Cemiplimab-rwlc (Libtayo®) Patient Management

To promote higher quality patient care, NCODA created the Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance document for healthcare providers. By providing quality standards and effective practices around a specific aspect of cancer care, each PQI equips the entire multidisciplinary care team with a sophisticated, concise resource for managing patients receiving oral or IV oncolytics. This PQI discusses patient management for Cemiplimab-rwlc (LIBTAYO®), an FDA-approved medication with indications for basal cell carcinoma, cutaneous squamous cell carcinoma and non-small cell lung cancer. Categorical disease states and treatment histories will be covered in this PQI. This article explores how the medically integrated teams at Allegheny Health Network and Memorial Cancer Institute incorporate PQIs in their daily workflow and how the LIBTAYO® PATIENT MANAGEMENT PQI elevates patient care.